Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies

Epigenomics

Volumn 2, Issue 2, 2010, Pages 233-243

  Hamilton, James P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 azacytidine; cholangiocarcinoma; epigenetics; HCC; hepatocellular carcinoma; histone modification; hypermethylation; hypomethylation; methylation; p16; RAS; sorafenib; zebularine

Indexed keywords

HISTONE;

APOPTOSIS; BILE DUCT CARCINOMA; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; DNA REPAIR; DNA SEQUENCE; EPIGENETICS; HEPATOBILIARY DISEASE; HUMAN; LIVER CELL CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 77954127482     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.9     Document Type: Review

References (81)

1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 (2007).
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
3. El-Serag HB, Engels EA, Landgren O et al.: Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of US veterans. Hepatology 49, 116-123 (2009).
4. Esteller M: Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).
5. Boyault S, Rickman DS, de Reynies A et al.: Transcriptome classifcation of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42-52 (2007).
6. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 31, 27-36 (2010).
7. Selaru FM, David S, Meltzer SJ, Hamilton JP: Epigenetic events in gastrointestinal cancer. Am. J. Gastroenterol. 104, 1910-1912 (2009).
8. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003).
9. Bestor TH: Transposons reanimated in mice. Cell 122, 322-325 (2005).
10. Feinberg AP, Cui H, Ohlsson R: DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin. Cancer Biol. 12, 389-398 (2002).
11. Reik W, Lewis A: Co-evolution of X-chromosome inactivation and imprinting in mammals. Nat. Rev. Genet. 6, 403-410 (2005).
12. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92 (1983).
13. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21-33 (2006).
14. Wilson AS, Power BE, Molloy PL: DNA hypomethylation and human diseases. Biochim. Biophys. Acta 1775, 138-162 (2007).
15. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413 (2002).
16. Fraga MF, Herranz M, Espada J et al.: A mouse skin multistage carcinogenesis model refects the aberrant DNA methylation patterns of human tumors. Cancer Res. 64, 5527-5534 (2004).
17. Fraga MF, Esteller M: Epigenetics and aging: the targets and the marks. Trends Genet. 23, 413-418 (2007).
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specifc PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996).
19. Dupont JM, Tost J, Jammes H, Gut IG: De novo quantitative bisulfte sequencing using the pyrosequencing technology. Anal. Biochem. 333, 119-127 (2004).
20. Weber M, Davies JJ, Wittig D et al.: Chromosome-wide and promoter-specifc analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37, 853-862 (2005).
21. Toyota M, Ho C, Ahuja N et al.: Identifcation of differentially methylated sequences in colorectal cancer by methylated CpG island amplifcation. Cancer Res. 59, 2307-2312 (1999).
22. Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell 128, 669-681 (2007).
23. Ballestar E, Paz MF, Valle L et al.: Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 22, 6335-6345 (2003).
24. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128, 683-692 (2007).
25. Ma X, Ezzeldin HH, Diasio RB: Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69, 1911-1934 (2009).
26. Esteller M: Cancer epigenomics: DNA methylomes and histone-modifcation maps. Nat. Rev. Genet. 8, 286-298 (2007).
27. Yang HI, Lu SN, Liaw YF et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 347, 168-174 (2002).
28. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 42, 1208-1236 (2005).
29. Hsu YS, Chien RN, Yeh CT et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35, 1522-1527 (2002).
30. Soini Y, Chia SC, Bennett WP et al.: An afatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 17, 1007-1012 (1996).
31. Yam JW, Wong CM, Ng IO: Molecular and functional genetics of hepatocellular carcinoma. Front. Biosci. (Schol. Ed.) 2, 117-134 (2010).
32. Baylin SB: Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin. Cancer Biol. 12, 331-337 (2002).
33. Calvisi DF, Ladu S, Gorden A et al.: Mechanistic and prognostic signifcance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 117, 2713-2722 (2007).
34. Roberts LR, Gores GJ: Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis. 25, 212-225 (2005).
35. Lee HS, Kim BH, Cho NY et al.: Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin. Cancer Res. 15, 812-820 (2009).
36. Lee JS, Chu IS, Heo J et al.: Classifcation and prediction of survival in hepatocellular carcinoma by gene expression profling. Hepatology 40, 667-676 (2004).
37. Aravalli RN, Steer CJ, Cressman EN: Molecular mechanisms of hepatocellular carcinoma. Hepatology 48, 2047-2063 (2008).
38. Ying Y, Tao Q: Epigenetic disruption of the WNT/p-catenin signaling pathway in human cancers. Epigenetics 4, 307-312 (2009).
39. Csepregi A, Rocken C, Hoffmann J et al.: APC promoter methylation and protein expression in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 134, 579-589 (2008).
40. Malumbres M, Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1, 222-231 (2001).
41. INK4A gene alterations in hepatocellular carcinoma. Oncogene 18, 789-795 (1999).
42. INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 116, 394-400 (1999).
43. Jin M, Piao Z, Kim NG et al.: p16 is a major inactivation target in hepatocellular carcinoma. Cancer 89, 60-68 (2000).
44. Roncalli M, Bianchi P, Bruni B et al.: Methylation framework of cell-cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 36, 427-432 (2002).
45. Lee S, Lee HJ, Kim JH et al.: Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. 163, 1371-1378 (2003). (Pubitemid 37175085)
46. Zhang YJ, Rossner P Jr, Chen Y et al.: Afatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int. J. Cancer 119, 985-991 (2006).
47. Zhang YJ, Wu HC, Shen J et al.: Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res. 13, 2378-2384 (2007).
48. Matsuda Y: Molecular mechanism underlying the functional loss of cyclin-dependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J. Gastroenterol. 14, 1734-1740 (2008).
49. INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res. 67, 5771-5778 (2007).
50. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ: Frequent p 15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res. 6, 3516-3521 (2000).
51. Newell P, Toffanin S, Villanueva A et al.: RAS pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 51, 725-733 (2009).
52. Yea S, Narla G, Zhao X et al.: RAS promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134, 1521-1531 (2008).
53. Yasuda E, Kumada T, Takai S et al.: Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 337, 337-342 (2005).
54. Tischoff I, Tannapfe A: DNA methylation in hepatocellular carcinoma. World J. Gastroenterol. 14, 1741-1748 (2008).
55. Yu J, Ni M, Xu J et al.: Methylation profling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2, 29 (2002).
56. Nomoto S, Kinoshita T, Kato K et al.: Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br. J. Cancer 97, 1260-1265 (2007).
57. Harder J, Opitz OG, Brabender J et al.: Quantitative promoter methylation ana lysis of hepatocellular carcinoma, cirrhotic and normal liver. Int. J. Cancer 122, 2800-2804 (2008).
58. Kwon GY, Yoo BC, Koh KC, Cho JW, Park WS, Park CK: Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules. J. Korean Med. Sci. 20, 242-247 (2005).
59. Hamilton JP, Sato F, Greenwald BD et al.: Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin. Gastroenterol. Hepatol. 4, 701-708 (2006).
60. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112, 1325-1336 (2008).
61. Hoque MO, Begum S, Brait M et al.: Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J. Urol. 179, 743-747 (2008).
62. Lu GL, Wen JM, Xu JM, Zhang M, Xu RB, Tian BL: [Relationship between TIMP-3 expression and promoter methylation of TIMP-3 gene in hepatocellular carcinoma]. Zhonghua Bing Li Xue Za Zhi 32, 230-233 (2003).
63. Glockner SC, Dhir M, Yi JM et al.: Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69, 4691-4699 (2009).
64. Wong CM, Ng YL, Lee JM et al.: Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45, 1129-1138 (2007).
65. Park JH, Cho SB, Lee WS et al.: [Methylation pattern of DNA repair genes and microsatellite instability in hepatocellular carcinoma]. Korean J. Gastroenterol. 48, 327-336 (2006).
66. Matsukura S, Soejima H, Nakagawachi T et al.: CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br. J. Cancer 88, 521-529 (2003).
67. 6 alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 7, 745-749 (1986).
68. Su PF, Lee TC, Lin PJ et al.: Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int. J. Cancer 121, 1257-1264 (2007).
69. Wang J, Qin Y, Li B, Sun Z, Yang B: Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin. Biochem. 39, 344-348 (2006).
70. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A: Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47, 908-918 (2008).
71. Boland CR, Shin SK, Goel A: Promoter methylation in the genesis of gastrointestinal cancer. Yonsei Med. J. 50, 309-321 (2009).
72. Lee H, Ryu SH, Hong SS et al.: Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. J. Gastroenterol. Hepatol. 24, 1445-1450 (2009).
73. Pogribny IP, Ross SA, Tryndyak V P, Pogribna M, Poirier LA, Karpinets TV: Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl defciency in rats. Carcinogenesis 27, 1180-1186 (2006).
74. Tischoff I, Markwarth A, Witzigmann H et al.: Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int. J. Cancer 115, 684-689 (2005).
75. Tischoff I, Wittekind C, Tannapfel A: Role of epigenetic alterations in cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 13, 274-279 (2006).
76. Selaru FM, Olaru AV, Kan T et al.: MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49, 1595-1601 (2009).
77. Doi A, Park IH, Wen B et al.: Differential methylation of tissue-and cancer-specifc CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fbroblasts. Nat. Genet. 41, 1350-1353 (2009).
78. Llovet JM, Ricci S, Mazzaferro V et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
79. Liu L, Cao Y, Chen C et al.: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66, 11851-11858 (2006).
80. Villanueva A, Chiang DY, Newell P et al.: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135, 1972-1983, 1983 E1-E11 (2008).
81. Calvisi DF, Ladu S, Gorden A et al.: Ubiquitous activation of RAS and JAK/STAT pathways in human HCC. Gastroenterology 130, 1117-1128 (2006).